Long-term safety and efficacy of fostamatinib in Japanese patients with primary immune thrombocytopenia
Open Access
- 28 January 2025
- journal article
- research article
- Published by Springer Nature in International Journal of Hematology
- Vol. 121 (3) , 356-362
Abstract
Fostamatinib had superior efficacy to a placebo and acceptable safety profiles for at least 1 year in a phase 3 study of Japanese patients with primary immune thrombocytopenia. Here, we report the 3-year safety and efficacy of fostamatinib in that study. Data from 33 patients who received at least one dose of fostamatinib were analyzed. A platelet response > 50,000/µL (at two consecutive visits at least 28 days apart while receiving fostamatinib) was achieved in 16 patients (48%). The median total duration of a platelet response > 50,000/µL was 589 (range: 106–1003) days. Gastrointestinal disorders, such as diarrhea, hypertension, and hepatic enzyme elevation, were the most common fostamatinib-related adverse events. Most events occurred within 12 weeks of treatment. No thromboembolisms, treatment-related infections, or moderate or severe treatment-related bleeding events were observed. In summary, this extension study of a clinical trial found a sustained platelet response without new safety signals during 3-year treatment with fostamatinib.Keywords
Funding Information
- Kissei
This publication has 16 references indexed in Scilit:
- Fostamatinib for the treatment of chronic immune thrombocytopeniaBlood, 2019
- Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial programAmerican Journal of Hematology, 2019
- Fostamatinib for Persistent/Chronic Adult Immune ThrombocytopeniaImmunotherapy, 2017
- The Novel Oral Syk Inhibitor, Bl1002494, Protects Mice From Arterial Thrombosis and Thromboinflammatory Brain InfarctionArteriosclerosis, Thrombosis, and Vascular Biology, 2016
- Immunomodulation and immune thrombocytopenia: some unmet needs, questions, and outlookSeminars in Hematology, 2016
- Is ITP a thrombophilic disorder?American Journal of Hematology, 2015
- Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopeniaBlood, 2012
- Critical role for Syk in responses to vascular injuryBlood, 2011
- Therapeutic Targeting of Syk in Autoimmune DiabetesThe Journal of Immunology, 2010
- R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated InflammationThe Journal of Pharmacology and Experimental Therapeutics, 2006